Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Nov

First Show Vienna! Phase I Clinical Data of the World's First Antibody Drug SGC001 for Acute Myocardial Infarction Unveiled BIO Europe2025

On November 3, 2025, Vienna time, Sungen announced the Phase I clinical results of SGC001 Injection, the world's first antibody drug for acute myocardial infarction, at the 31st BIO Europe 2025, h...

Read article >

Nov

A major breakthrough! A phase Ib clinical study of SGC001, a “global pioneer” antibody drug for acute myocardial infarction by Sungen, has achieved positive results

Recently, a phase Ib clinical study of SGC001 Injection, the world's first antibody drug for acute myocardial infarction, developed by Sungen, has obtained positive preliminary results. The data s...

Read article >

Nov

Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs is established to help China break through the global of innovative drugs

On September 24, the "Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs", co-sponsored by a number of industry leading institutions and enterprises such as Hotge...

Read article >